MAMMOGRAPHY SCREENING PROGRAM "DONNA" SIGNIFICANTLY REDUCES OVERALL MORTALITY OF WOMEN WITH BREAST CANCER

(1) University of St. Gallen, School of Medicine, Chair of Healthcare Management, St. Gallen, Switzerland, (2) Krebsliga Ostschweiz, St. Gallen, Switzerland Marcel Blum (2), Jonas Subelack (1), David Kuklinski (1), Alexander Geissler (1), Alena Eichenberger (2), Rudolf Morant (2)







AIM & OBJECTIVES

Each year 550 women in the cantons of St.Gallen and Graubünden are diagnosed with breast cancer (BC) – 500 of them with invasive BC

- 2010 the organized mammography screening program (MSP) "donna" is active in these cantons – all women between 50 and 69 are every two years invited to participate
- The participation rate has been increasing up to recent 52% - around 36,000 women participate each year
- "donna" helps to diagnose BC at an earlier stage thus giving the women less invasive treatment options and a more favorable prognosis [1, 2]
- Our aim is to compare the survival rates of women whose BC was diagnosed through the "donna" MSP to those who did not participate in the program

PATIENTS & METHODS


- Data of 2'701 BC tumors diagnosed between 2010 and 2019* of 2'598 women aged 50 to 69 in the cantons of St.Gallen and Graubünden were used**
- BC tumors were classified either as
 - Detected in the "donna" MSP
 - Screening-Detected Cases (SDC) after a positive mammography (N = 883, 32.7%)
 - Interval-Carcinomas (IC) diagnosed within 24 months after a negative mammography (N = 251, 9.3%)
 - Outside MSP diagnosed BC cases (N = 1,567, 58.0%)
- We analyze the UICC-TNM stage distribution, tumor characteristics, treatments, and the survival of the women using 1-, 2-, 5- and 7-year overall survival rates as well as Kaplan-Meier estimates
- Wilcoxon-Mann-Whitney or Student's t-tests, and Greenwood Point estimators for the Kaplan-Meier estimates respectively, were used for calculating the significance of the results
- * Year of the diagnosis (SDC, outside MSP) or the mammography (IC)
- ** Data Sources:

Cancer Registry of Eastern Switzerland and Cancer Registry of Graubünden-Glarus www.krebsregister-ost.ch www.ksgr.ch/krebsregister

donna Mammography Screening Program www.donna-programm.ch

RESULTS


BC diagnosed in the "donna" MSP have a significantly higher share of in-situ and stage I carcinomas (64.1% vs. 43.4%, p<0.001) and have significantly fewer metastases at diagnoses, i.e., stage IV tumors (2.7% vs. 11.6%, p<0.001)



- Women with a BC diagnosed in the "donna" MSP have
 - a smaller mean tumor size (19.0mm vs. 24.9mm, p<0.001)
 - less chemotherapies (27.6% vs. 39.9%, p<0.001)
 - fewer radical mastectomies (8.9% vs. 17.7%, p<0.001)
 - less often a recurrence or metastasis in the follow-up period (5.5% vs. 14.4%, p<0.001)
- Significantly higher survival rates of women with BC diagnosed in the "donna" MSP

Overall	1	2	5	7
Survival Rates	year	years	years	years
"donna" MSP	99.7%	99.1%	96.5%	94.3%
outside MSP	97.0%	93.8%	86.1%	80.9%

- Kaplan-Meier significantly estimates show differences between these groups independent of the UICC-TNM stages, e.g., stage I
- Women with their BC diagnosed in the donna MSP
 - have a higher 10-year overall survival rate by 18 percent-points (Hazard Ratio: 0.30)
 - have a higher 10-year survival rate in stage I by 10 percent-points (Hazard Ratio: 0.32)



CONCLUSIONS & DISCUSSION

- Women with BC diagnosed in the "donna" MSP have a significantly higher overall survival rate than women diagnosed outside the program
- Detection of breast cancer at an earlier stage can only partially explain the results, as results persisted even when accounting for tumor stage
- results show the effectiveness of our mammography screening program to decrease mortality rates for breast cancer, thus confirming other foreign studies [3, 4]
- Potential lead and selection bias Socioeconomic factors influence the participation rate [5] and thus could be at least a partial explanation for the better survival due to their healthier lifestyle
- The study only includes data from two cantons (8.2% of the Swiss population) and a limited observation time – hence the number of patients is rather small
- Further analysis will be conducted, such as the impact of hormone receptors, e.g., progesterone, estrogen, or HER2
- Data from other MSP and/or cantons should be used for comparison of our results

REFERENCES

- Herrmann, C., Morant, R., Walser, E., Mousavi, M., & Thürlimann, B. (2021). Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC cancer, 21, 1-6.
- Molassiotis, A., Tyrovolas, S., Giné-Vázquez, I., Yeo, W., Aapro, M., & Herrstedt, J. (2021). Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disabilityadjusted life years: analysis of the Global Burden of Disease Study and screening programme availability in 130 countries. ESMO open, 6(3), 100111.
- Iwamoto, Y., Kaucher, S., Lorenz, E., Bärnighausen, T., & Winkler, V. (2019). Development of breast cancer mortality considering the implementation of mammography screening programs-a comparison of western European countries. BMC public health, 19, 1-9.
- Katalinic, A., Eisemann, N., Kraywinkel, K., Noftz, M. R., & Hübner, J. (2020). Breast cancer incidence and mortality before and after implementation of the German mammography screening program. International journal of cancer, 147(3), 709-718.
- Jolidon, V., De Prez, V., Bracke, P., Bell, A., Burton-Jeangros, C., & Cullati, S. (2022). Revisiting the effects of organized mammography programs on inequalities in breast screening uptake: a multilevel analysis of nationwide data from 1997 to 2017. Frontiers in Public Health, 10, 812776.

CONTACT

Rudolf Morant, Krebsliga Ostschweiz

- Address: Krebsliga Ostschweiz, Flurhofstrasse 7, CH-9000 St.Gallen
- Mail: Rudolf.Morant@krebsliga-ostschweiz.ch

Marcel Blum, Krebsliga Ostschweiz

Address: Krebsliga Ostschweiz, Flurhofstrasse 7, CH-9000 St.Gallen Mail: Marcel.Blum@krebsliga-ostschweiz.ch